Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company. Our vision is a world where all patients with rare immunologic diseases can lead long and healthy lives. But we often see that people with rare diseases are relegated to the impossible and left to fend for themselves. That's not the way forward. We see all patients as equal individuals with individual needs. A point of view that gives us a unique ability to deliver the most inclusive care to everyone. For us the mission is clear – we want to develop lifesaving and life altering therapies to those who need them the most. And ultimately, we can – and will – eliminate rare diseases, one patient at a time. So how do we aim to achieve our goal?• We partner with global scientific, medical, and patient communities to identify the most urgent needs• We work relentlessly to meet the needs and create lifesaving treatments• Our lead program enables kidney transplantation in difficult-to-transplant patients, with additional clinical studies ongoing for the treatment of several acute and chronic autoimmune conditionsFollow us on our journey, and we will keep you up to speed on our work to make rare diseases rarer.About us• We are based in Lund, Sweden and have operations in other European countries and in the United States• We are a biopharmaceutical company engaged in clinical development, drug discovery and commercialization• We are specialized in rare diseases within transplantation, autoimmunity, oncology and gene therapy• We are listed on Nasdaq Nordic

Biopharmaceuticals Clinical development Drug discovery In vitro diagnostics Kidney transplantation Autoimmune disease Sepsis Antibody glycosylation Orphan drug Immunomodulatory Biopharmaceuticals Clinical development Drug discovery In vitro diagnostics Kidney transplantation Autoimmune disease Sepsis Antibody glycosylation Orphan drug Immunomodulatory Biopharmaceuticals Clinical development Drug discovery In vitro diagnostics Kidney transplantation Autoimmune disease Sepsis Antibody glycosylation Orphan drug Immunomodulatory Rare diseases